Zobrazeno 1 - 5
of 5
pro vyhledávání: '"556"'
Autor:
Kentaro Kishi, Yasuo Urata, Masaki Mori, Kenta Furukawa, Toshimitsu Irei, Masaki Wakasugi, Masashi Inoue, Shinya Yamashita, Yuichiro Doki, Masahiro Tanemura, Hiroaki Nagano, Nobuyoshi Hatanaka, Hiroki Akamatsu
Publikováno v:
Cancer Research. 75:556-556
Circulating tumor cells (CTCs) are thought to be “metastatic intermediates”. Recently, we reported encouraging survival rates following neoadjuvant therapy using gemcitabine (Gem) and S-1 concurrently with radiotherapy (NACRT) in patients (pts) w
Publikováno v:
Cancer Research. 81:PO-051
Tumor Treating Fields (TTFields) are a non-invasive, loco-regional antimitotic treatment modality, approved for the treatment of glioblastoma and malignant pleural mesothelioma. TTFields at a specific frequency (150-200 kHz) are delivered via arrays
Autor:
Xiaojia Wang, Zefei Jiang, Guyin Lou, Biyun Wang, Zhongsheng Tong, Binghe Xu, Jianfeng Luo, Y. Pan, Zhimin Shao, Yongmei Yin, Li Cai, Changping Wu, Donggeng Liu, Jifeng Feng, Y. Teng, Zhonghua Wang, Joseph Ragaz, Jian Zhang, Xichun Hu, Jiong Wu
Publikováno v:
Cancer Research. 75:P3-10
Background: There is still no standard chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC). Our previous phase II pilot trial with first-line gemcitabine and cisplatin combination (GP) in patients with mTNBC (clinicaltrial
Publikováno v:
Cancer Research. 79:CT176-CT176
Background: Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality, which has been approved for the treatment of patients with glioblastoma by the FDA. TTFields predominantly act by disrupting the formation of th
Publikováno v:
Cancer Research. 78:CT157-CT157
Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality, which has been approved for the treatment of patients with glioblastoma by the FDA. TTFields predominantly act by disrupting the formation of the mitotic sp